The trajectory of the erectile dysfunction drug presents a complex picture for shareholders. While the initial introduction generated massive profits, the lapse of its patent opened the avenue to generic competitors, https://bookmarkspecial.com/story21819519/sildenafil-and-the-pharmaceutical-industry-a-risky-bet